2012 Formulary Reference Guide
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Clinical Study Is Nonmicronized Diosmin 600Mg As Effective As
Hindawi International Journal of Vascular Medicine Volume 2020, Article ID 4237204, 9 pages https://doi.org/10.1155/2020/4237204 Clinical Study Is Nonmicronized Diosmin 600mg as Effective as Micronized Diosmin 900mg plus Hesperidin 100mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study Marcio Steinbruch,1 Carlos Nunes,2 Romualdo Gama,3 Renato Kaufman,4 Gustavo Gama,5 Mendel Suchmacher Neto,6 Rafael Nigri,7 Natasha Cytrynbaum,8 Lisa Brauer Oliveira,9 Isabelle Bertaina,10 François Verrière,10 and Mauro Geller 3,6,9 1Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020 2Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis- Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 3Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 4Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903 5Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200 6Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200 7Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA 8Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020 9Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av. -
(12) United States Patent (10) Patent No.: US 6,692,728 B2 Weipert Et Al
USOO6692728B2 (12) United States Patent (10) Patent No.: US 6,692,728 B2 Weipert et al. (45) Date of Patent: Feb. 17, 2004 (54) POLYESTERS BASED ON HYDROXY FATTY (52) U.S. Cl. ......................... 424/59; 424/497; 424/489; ACDS AND LOWER HYDROXY ALKYL 424/70.11; 424/78.37; 424/78.08; 514/785; ACDS AND USES THEREOF 560/171; 560/172; 560/176; 560/183; 525/400 (58) Field of Search .......................... 424/59, 497, 489, (75) Inventors: Paul David Weipert, High Point, NC 424/70.11, 78.37; 514/785; 560/172,176, (US); Bharat B. Desai, Spartanburg, 183; 525/400 SC (US) (73) Assignee: Ethox Chemicals LLC, Greenville, SC ") References Cited (US) U.S. PATENT DOCUMENTS ( c: ) Notice: Subject to any disclaimer, the term of this 5,502,116 A 3/1996 Noda ......................... 525/415 patent is extended or adjusted under 35 5,614,576 A * 3/1997 Rutherford et al. ......... 524/270 U.S.C. 154(b) by 0 days. 5,851,937 A * 12/1998 Wu et al. ................... 442/394 * cited by examiner (21) Appl. No.: 10/388,426 (22) Filed: Mar 17, 2003 Primary Examiner Sabiha Qazi 9 (74) Attorney, Agent, or Firm-Isaac A. Angres (65) Prior Publication Data (57) ABSTRACT US 2003/0175222 A1 Sep. 18, 2003 The present invention provides biodegradable polyesters Related U.S. Application Data based on lower hydroxy acids and hydroxy fatty acids. The resulting polyesters are useful as cosmetic vehicles for (62) Division of application No. 09/805,894, filed on Mar. 15, Sunscreens, skin lotions and by themselves are also useful as 2001, now Pat. -
Penetration of Synthetic Corticosteroids Into Human Aqueous Humour
Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography). -
The Benefits of Flavonoids in Diabetic Retinopathy
nutrients Review The Benefits of Flavonoids in Diabetic Retinopathy 1, 1, 2,3,4,5 1,2,3,4, Ana L. Matos y, Diogo F. Bruno y, António F. Ambrósio and Paulo F. Santos * 1 Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal; [email protected] (A.L.M.); [email protected] (D.F.B.) 2 Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal; [email protected] 3 Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal 4 Clinical Academic Center of Coimbra (CACC), 3004-561 Coimbra, Portugal 5 Association for Innovation and Biomedical Research on Light and Image (AIBILI), 3000-548 Coimbra, Portugal * Correspondence: [email protected]; Tel.: +351-239-240-762 These authors contributed equally to the work. y Received: 10 September 2020; Accepted: 13 October 2020; Published: 16 October 2020 Abstract: Diabetic retinopathy (DR), one of the most common complications of diabetes, is the leading cause of legal blindness among adults of working age in developed countries. After 20 years of diabetes, almost all patients suffering from type I diabetes mellitus and about 60% of type II diabetics have DR. Several studies have tried to identify drugs and therapies to treat DR though little attention has been given to flavonoids, one type of polyphenols, which can be found in high levels mainly in fruits and vegetables, but also in other foods such as grains, cocoa, green tea or even in red wine. -
[email protected]
SAFETY DATA SHEET Revision Date 13-Jul-2016 Version 1 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING Product identifier Product Name Pred Forte Other means of identification Product Code FP61 Synonyms Prednisolone Acetate Recommended use of the chemical and restrictions on use Recommended Use Corticosteroid This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient. Details of the supplier of the safety data sheet Manufacturer ALLERGAN 400 Interpace Parkway, Morris Corporate Center III Parsippany, NJ 07054, USA +1-800-272-5525 E-mail address [email protected] Emergency telephone number Emergency Telephone Call CHEMTREC Day or Night Within USA or Canada: 1-800-424-9300 Outside USA and Canada: +1-703-741-5970 (collect calls accepted) 2. HAZARDS IDENTIFICATION Classification OSHA Regulatory Status This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Reproductive toxicity Category 2 Effects on or via lactation Yes Label elements Emergency Overview Danger Hazard statements H362 - May cause harm to breast-fed -
NINDS Custom Collection II
ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC -
Other Statutory Disclosures Continued
Other statutory disclosures continued Strategic reportGroup companies Governance & remuneration Financial statements In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the country of incorporation and effective percentage of equity owned, as at 31 December 2015 are disclosed below. Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GlaxoSmithKline plc. All subsidiary companies are resident for tax purposes in their country of incorporation unless otherwise stated. Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries 1506369 Alberta ULC Canada 100 Common 100 Action Potential Venture Capital Limited England & Wales 100 Ordinary 100 Adechsa GmbH Switzerland 100 Ordinary 100 Affymax Research Institute United States 100 Common 100 Alenfarma – Especialidades Farmaceuticas, Limitada (iv) Portugal 100 Ordinary Quota 100 Allen & Hanburys Limited (iv) England & Wales 100 Ordinary 100 Allen & Hanburys Pharmaceutical Nigeria Limited Nigeria 100 Ordinary 100 Allen Farmaceutica, S.A. Spain 100 Ordinary 100 Allen Pharmazeutika Gesellschaft m.b.H. Austria 100 Ordinary 100 Aners S.A (iv) Argentina 100 Non-endorsable Nominative Ordinary 100 Barrier Therapeutics, Inc. United States 100 Common 100 Beecham Group p l c England & Wales 100 20p Shares 'A'; 5p Shares B 100 Beecham Pharmaceuticals (Pte) Limited Singapore 100 Ordinary 100 Beecham Pharmaceuticals S.A (iv) (vi) Ecuador 100 Nominative 100 Beecham Portuguesa-Produtos Farmaceuticos e Quimicos, Lda Portugal 100 Ordinary Quota 100 Beecham S.A. (iv) Belgium 100 Ordinary 100 Biddle Sawyer Limited India 100 Equity 100 Biovesta Ilaçlari Ltd. Sti. Turkey 100 Nominative 100 Burroughs Wellcome & Co (Australia) Pty Limited (iv) (vi) Australia 100 Ordinary 100 Burroughs Wellcome & Co (Bangladesh) Limited Bangladesh 100 Ordinary 100 Burroughs Wellcome International Limited England & Wales 100 Ordinary 100 Caribbean Chemical Company, Ltd. -
Prednisolone Also Binds to Transcortin • Other Synthetic GS Only Bind to Albumin
PK/PD considerations for corticosteroids P L Toutain, National Veterinary School, Toulouse, France Wuhan October 2015 1 Anti-inflammatory drugs Corticosteroids NSAIDs 2 Glucocorticoids: main properties • Glucocorticosteroids (GCS) are broad and potent anti- inflammatory drugs. • They are extensively used to mitigate or suppress inflammation associated with a variety of conditions especially joint and respiratory system inflammation. • GCs are not curative: • GCs are only palliative symptomatic treatments and chronic use of GCs can be, in fine , detrimental • GCs possess many other pharmacological properties (not reviewed in this presentation) 3 The cortisol or hydrocortisone 4 Cortisol : An endogenous hormone and a surrogate endpoint of the duration of the GCS effects; it physiology should be understood to use properly GCS 5 Cortisol synthesis • All GCs used in therapeutics are synthetic derivatives of cortisol. • Cortisol (hydrocortisone) is synthesized in the adrenal cortex and it is the main corticosteroid hormone in most species. 6 Steroids synthesis by the adrenal gland Aldosterone Cortisol Androgens Epinephrine (adrenalin) 7 Cortisol ou Hydrocortisone structure – activity relationship Three structural properties are required for a GC activity (i.e. for cortisol to bind to GC receptor) 8 Cortisol (hydrocortisone) • Minimal information on cortisol physiology (secretion, distribution & elimination ) needs to be known to understand the clinical pharmacology of GCS 9 Plasma cortisol • Cortisol levels are very different in domestic species • Pattern of secretion – Circadian rhythm (h) – Pulsatilty (minute) 10 Plasma cortisol level Plasma concentration (ng/mL) 600 500 400 300 Series1 200 100 0 1 2 3 4 5 11 Plasma cortisol levels: circadian rhythm & pulsatility Toutain et al. Domestic.Anim.Endocrinol. -
Chondroprotective Agents
Europaisches Patentamt J European Patent Office © Publication number: 0 633 022 A2 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 94109872.5 © Int. CI.6: A61K 31/365, A61 K 31/70 @ Date of filing: 27.06.94 © Priority: 09.07.93 JP 194182/93 Saitama 350-02 (JP) Inventor: Niimura, Koichi @ Date of publication of application: Rune Warabi 1-718, 11.01.95 Bulletin 95/02 1-17-30, Chuo Warabi-shi, 0 Designated Contracting States: Saitama 335 (JP) CH DE FR GB IT LI SE Inventor: Umekawa, Kiyonori 5-4-309, Mihama © Applicant: KUREHA CHEMICAL INDUSTRY CO., Urayasu-shi, LTD. Chiba 279 (JP) 9-11, Horidome-cho, 1-chome Nihonbashi Chuo-ku © Representative: Minderop, Ralph H. Dr. rer.nat. Tokyo 103 (JP) et al Cohausz & Florack @ Inventor: Watanabe, Koju Patentanwalte 2-5-7, Tsurumai Bergiusstrasse 2 b Sakado-shi, D-30655 Hannover (DE) © Chondroprotective agents. © A chondroprotective agent comprising a flavonoid compound of the general formula (I): (I) CM < CM CM wherein R1 to R9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The 00 00 above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to (Q protect cartilage, and thus, is extremely effective for the treatment of arthropathy. Rank Xerox (UK) Business Services (3. 10/3.09/3.3.4) EP 0 633 022 A2 BACKGROUND OF THE INVENTION 1 . Field of the Invention 5 The present invention relates to an agent for protecting cartilage, i.e., a chondroprotective agent, more particularly, a chondroprotective agent containing a flavonoid compound or a stereoisomer thereof, or a naturally occurring glycoside thereof. -
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine -
Assessment Report on Ricinus Communis L., Oleum Final
2 February 2016 EMA/HMPC/572973/2014 Committee on Herbal Medicinal Products (HMPC) Assessment report on Ricinus communis L., oleum Final Based on Article 10a of Directive 2001/83/EC as amended (well-established use) Herbal substance(s) (binomial scientific name Ricinus communis L., oleum (castor oil) of the plant, including plant part) Herbal preparation Fatty oil obtained from seeds of Ricinus communis L. by cold expression Pharmaceutical forms Herbal preparation in liquid or solid dosage forms for oral use Rapporteur C. Purdel Peer-reviewer B. Kroes 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ................................................................................................................... 2 1. Introduction ....................................................................................................................... 4 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4 1.2. Search and assessment methodology ..................................................................... 6 2. Data on medicinal use ........................................................................................................ 6 2.1. Information about products on the market ............................................................. -
In This Section
Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.